论文部分内容阅读
Breast cancers with erbB2 alterations are more aggressive and typically more resistant to traditional therapeutic agents.Thus, the erbB2 receptor is an excellent target for breast cancer therapy.Herceptin (Trastuzumab), a humanized monoclonal antibody, was the first erbB2-targeted therapy approved by FDA.Although Herceptin has been successfully used in erbB2-overexpressing breast cancers, both primary and treatment-acquired resistances to Herceptin are common and currently represent a significant clinical problem.